美国2013-2017年医疗器械与操作相关感染大肠埃希菌多重耐药监测
基于美国国家医疗安全网络2013-2017年96 672株大肠埃希菌分离株数据,分析医疗器械与操作相关医疗保健相关感染中多重耐药表型的分布与趋势。结果显示35%对氟喹诺酮类不耐药、17%对超广谱头孢菌素不敏感、13%对两者均耐药;对两者共耐药比例从2013年11%升至2017年14%(P<.0001),且在不同医院转诊区域分布不均。共耐药独立相关因素包括男性、中心静脉导管相关血流感染、长期急性护理医院及2016-2017报告期。
要点
- 2013-2017年器械/操作相关感染大肠埃希菌中,13%对氟喹诺酮类与超广谱头孢菌素共耐药
- 共耐药比例从2013年11%升至2017年14%,在地理区域间分布不均
- 共耐药独立相关因素包括男性、中心静脉导管相关血流感染、长期急性护理医院
核心结论
- 美国器械与操作相关医疗保健相关感染中,大肠埃希菌多重耐药呈上升趋势。
- 氟喹诺酮类与超广谱头孢菌素共耐药菌株在不同医院转诊区域间呈异质性传播。
研究设计与样本
- 基于美国国家医疗安全网络2013-2017年报告的急性护理医院、长期急性护理医院及住院康复机构分离株与药敏数据。
- 共纳入96 672株大肠埃希菌分离株,采用多变量logistic回归分析共耐药表型与患者、机构特征及时间的关联。
主要发现
- 患者中位年龄62岁,60%为女性,54%分离株来自导管相关尿路感染。
- 2013-2017年,35%分离株对氟喹诺酮类不敏感,17%对超广谱头孢菌素不敏感,13%对两者均耐药。
- 对超广谱头孢菌素与氟喹诺酮类共耐药比例2017年(14%)高于2013年(11%)(P < .0001)。
- 共耐药独立相关因素包括男性、中心静脉导管相关血流感染、长期急性护理医院及2016-2017报告期(vs 2013-2014)。
关键数值与推荐
- 共耐药定义为对超广谱头孢菌素和氟喹诺酮类均不敏感。
- 2013-2017年共耐药比例为13%,2017年升至14%(P < .0001)。
临床怎么用
- 在器械或操作相关感染中经验性覆盖大肠埃希菌时,需考虑氟喹诺酮类与超广谱头孢菌素共耐药的地域差异。
- 对长期急性护理医院、中心静脉导管相关血流感染及男性患者应加强耐药监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Escherichia coli is one of the most common causes of healthcare-associated infections (HAIs); multidrug resistance reduces available options for antibiotic treatment. We examined factors associated with the spread of multidrug-resistant E. coli phenotypes responsible for device- and procedure-related HAIs from acute care hospitals, long-term acute care hospitals, and inpatient rehabilitation facilities, using isolate and antimicrobial susceptibility data reported to the National Healthcare Safety Network during 2013-2017. METHODS: We used multivariable logistic regression to examine associations between co-resistant phenotypes, patient and healthcare facility characteristics, and time. We also examined the geographic distribution of co-resistant phenotypes each year by state and by hospital referral region to identify hot spots. RESULTS: A total of 96 672 E. coli isolates were included. Patient median age was 62 years, and 60% were female; more than half (54%) were reported from catheter-associated urinary tract infections. From 2013 to 2017, 35% of the isolates were nonsusceptible to fluoroquinolones (FQs), 17% to extended-spectrum cephalosporins (ESCs), and 13% to both ESCs and FQs. The proportion of isolates co-resistant to ESCs and FQs was higher in 2017 (14%) than in 2013 (11%) (P < .0001); overall prevalence and increases were heterogeneously distributed across healthcare referral regions. Co-resistance to FQs and ESCs was independently associated with male sex, central line-associated bloodstream infections, long-term acute care hospitals, and the 2016-2017 (vs 2013-2014) reporting period. CONCLUSIONS: Multidrug resistance among E. coli causing device- and procedure-related HAIs has increased in the United States. FQ and ESC co-resistant strains appear to be spreading heterogeneously across hospital referral regions.
引用
- Kourtis AP, Sheriff EA, Weiner-Lastinger LM, et al. Antibiotic Multidrug Resistance of Escherichia coli Causing Device- and Procedure-related Infections in the United States Reported to the National Healthcare Safety Network, 2013-2017. Clin Infect Dis. 2021. PMID: 32702102. doi:10.1093/cid/ciaa1031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。